drug efficacy paclitaxel social marketing exercise cancer genetics bioinformatics genetic screening breast cancer abdominal obesity terminal care lifestyle modification stereotactic body radiation therapy protein kinase lkb1 cost effectiveness analysis protein p53 physical activity genetic susceptibility bone metastasis ganetespib signal transduction cancer susceptibility pertuzumab raloxifene caloric restriction atm protein medical research cancer prognosis epithelial mesenchymal transition cognitive therapy radiofrequency ablation body weight psychological well being genetic variability denosumab nonhuman body composition cell lineage radiosensitivity behavior change smoking fenretinide malignant transformation phase 3 clinical trial topic genetic association single nucleotide polymorphism brca2 protein everolimus genotype metformin human resveratrol hormonal therapy phosphatidylinositol 3 low drug dose meta analysis topic cell death fine needle aspiration biopsy cell polarity afatinib cancer immunotherapy mastectomy positron emission tomography genetic predisposition saracatinib tamoxifen cytology patient satisfaction tumor microenvironment neratinib epigenetics in vitro study chemosensitivity luminespib lymphangiogenesis lapatinib quality of life surgery cancer epidemiology allele longevity breast metastasis brca1 protein checkpoint kinase 2 angiogenesis micrometastasis lasofoxifene randomized controlled trial topic tumor xenograft cancer risk dna damage distant metastasis alcohol consumption clinical decision making monotherapy trastuzumab breast reconstruction nuclear magnetic resonance imaging molecularly targeted therapy in vivo study goserelin gene expression cancer adjuvant therapy breast development translational research cancer survival biological marker fat intake advanced cancer uvomorulin 5 trisphosphate 3 phosphatase medicine and health sciences letrozole cancer hormone therapy personalized medicine circulating tumor cell